Babak Dehghani, Mohammad Mirzaei, Azadeh Lohrasbi-Nejad
{"title":"Characterization of Thermoresponsive Poly(N-vinylcaprolactam) Polymer Containing Doxorubicin-Loaded Niosomes: Synthesis, Structural Properties, and Anticancer Efficacy","authors":"Babak Dehghani, Mohammad Mirzaei, Azadeh Lohrasbi-Nejad","doi":"10.1007/s12247-024-09913-y","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Nanotechnology creates materials for medical purposes, such as nanocarriers or smart polymers that target and treat diseases like cancer.</p><h3>Methods</h3><p>In this study, hybrid carriers based on doxorubicin/poly(N-vinylcaprolactam) (DOX-PVCL) and doxorubicin-loaded niosome /poly(N-vinylcaprolactam) (DOX-Nio-PVCL) have been constructed as thermoresponsive polymers. At first, PVCL was synthesized and purified. Then, the DOX-Nio was prepared by the thin layer evaporation method and loaded into the PVCL. Furthermore, doxorubicin was loaded on PVCL by the same method. The structure features and morphology of the synthesized particles were determined using Fourier-transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (NMR), Raman spectroscopy, and electron microscopy. The synthesized particles’ size was measured at 25˚C and 37˚C by dynamic light scattering (DLS).</p><h3>Results</h3><p>The lower critical solution temperature (LCST) was determined and showed 32.5, 28.5, 28.5 ˚C values for PVCL, DOX-Nio-PVCl, and DOX-PVCL dissolved in phosphate-buffered saline, respectively. The release behavior of doxorubicin showed that the synthesized formulations had more potential release at pH 5.5 than pH 7.4. Evaluation of the cytotoxicity of PVCL on MCF-7 did not show any significant toxicity for concentrations 5.8–29 µg/mL. MCF-7 cell viability was investigated in the presence of DOX, DOX-Nio, DOX-Nio-PVCL, and DOX-PVCL at a final concentration of 29 µg/mL and 1.1 µg/mL of polymer and drug, respectively. Our results showed the highest MCF-7 cell death in DOX-PVCL-treated cells.</p><h3>Conclusion</h3><p>While the synthetic polymer displayed promising abilities in eliminating cancer cells, further study is necessary to explore its potential as a medicinal treatment, particularly in understanding its impact on in vivo structures.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-024-09913-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
Nanotechnology creates materials for medical purposes, such as nanocarriers or smart polymers that target and treat diseases like cancer.
Methods
In this study, hybrid carriers based on doxorubicin/poly(N-vinylcaprolactam) (DOX-PVCL) and doxorubicin-loaded niosome /poly(N-vinylcaprolactam) (DOX-Nio-PVCL) have been constructed as thermoresponsive polymers. At first, PVCL was synthesized and purified. Then, the DOX-Nio was prepared by the thin layer evaporation method and loaded into the PVCL. Furthermore, doxorubicin was loaded on PVCL by the same method. The structure features and morphology of the synthesized particles were determined using Fourier-transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (NMR), Raman spectroscopy, and electron microscopy. The synthesized particles’ size was measured at 25˚C and 37˚C by dynamic light scattering (DLS).
Results
The lower critical solution temperature (LCST) was determined and showed 32.5, 28.5, 28.5 ˚C values for PVCL, DOX-Nio-PVCl, and DOX-PVCL dissolved in phosphate-buffered saline, respectively. The release behavior of doxorubicin showed that the synthesized formulations had more potential release at pH 5.5 than pH 7.4. Evaluation of the cytotoxicity of PVCL on MCF-7 did not show any significant toxicity for concentrations 5.8–29 µg/mL. MCF-7 cell viability was investigated in the presence of DOX, DOX-Nio, DOX-Nio-PVCL, and DOX-PVCL at a final concentration of 29 µg/mL and 1.1 µg/mL of polymer and drug, respectively. Our results showed the highest MCF-7 cell death in DOX-PVCL-treated cells.
Conclusion
While the synthetic polymer displayed promising abilities in eliminating cancer cells, further study is necessary to explore its potential as a medicinal treatment, particularly in understanding its impact on in vivo structures.
期刊介绍:
The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories:
Materials science,
Product design,
Process design, optimization, automation and control,
Facilities; Information management,
Regulatory policy and strategy,
Supply chain developments ,
Education and professional development,
Journal of Pharmaceutical Innovation publishes four issues a year.